Galidesivir HCl (BCX4430; Immucillin-A)

Description: Galidesivir, formerly known as BCX-4430 and Immucillin-A, is an adenosine analog and antiviral drug and an adenosine analogue. Galidesivir was originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. Galidesivir also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BCX4430 has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection.

References:

1. TaylorR, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleosideanalog under development for the treatment of Ebola virus disease. JInfect Public Health. 2016; 9(3):220-226.

2. ElfikyAA, et al. ICN-1229, Remdesivir, PSI-7977, Galidesivir, and GS 1278against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A moleculardocking study. Life Sci. 2020 Mar 25:117592.

3. WarrenTK, et al. Protection against filovirus diseases by a novelbroad-spectrum nucleoside analogue BCX4430. Nature.2014; 508(7496):402-405.

4. JulanderJG, et al. BCX4430, a novel nucleoside analog, effectively treatsyellow fever in a Hamster model. Antimicrob Agents Chemother.2014; 58(11):6607-6614.

Related CAS #: 222631-44-9 (HCl) 249503-25-1 (free base)